Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 18 and 79 years.
- People with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) that has a specific gene change called an EGFR mutation.
- People whose cancer has one of two specific EGFR mutations: an Exon 19 deletion or a change called L858R.
- People who have completed at least two cycles of a first-line treatment called osimertinib, where the best result was that the cancer stayed stable or progressed slowly.
- People with a life expectancy of more than 3 months.
- People who have at least one measurable tumour that has not been previously treated with radiation, can be measured on a chest CT or PET-CT scan with specific size requirements, and can be reliably measured more than once over time.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently receiving or planning to receive other cancer-fighting treatments.
- People who have medical reasons that make it unsafe to take osimertinib or etoposide.
- People whose cancer is known to have specific genetic changes that cause resistance to osimertinib.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-23-68757791
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Objective Remission Rate (ORR) as assessed by RECIST v1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.